Xiaomeng Hu

Xiaomeng Hu has a master’s degree in pharmaceutics from Huazhong University of Science and Technology in China. Her thesis project is developing the self-adjuvant nanovaccine. She spent one and a half years investigating the applications of exosomes in cancer vaccines and treatment for inflammatory diseases at Karolinska Institute in Sweden. After that, Xiaomeng received the opportunity to work on a pharmaceutical project to develop the carrier-free vaccine for personalised treatment at EPFL, supported by the EPFLinnovators programme.